The 3Ps of Digital Endpoint Value | Public Launch Event
April 7, 2022
Director of Clinical Analytics and Research, Digital Care Delivery at Anthem, Inc
Medical Director, Digital Technology at Anthem, Inc
Global Value & Access at Biogen Digital Health
Senior Director, Strategic Partnerships at Evidation
Senior Director, Key Account Strategic Solutions at Evidation Health
Senior Director, Data Science Portfolio Management at Johnson & Johnson
Research Advisor, Global Patient Outcomes and Real World Evidence at Eli Lilly
Director, Value, Evidence, and Outcomes at Eli Lilly and Company
Executive Director, Head of Global Digital Analytics & Technologies at Merck
Executive Director Marketing, New Product Leader Neuroscience & Pain Portfolio at Merck
Senior Director, Commercial Development, Internal Medicine at Pfizer
Our industry has spent years working to develop the evidentiary best practices to try and ensure that regulators accept evidence from digital endpoints in support of new drug approvals. But, to date, we’ve thought very little about how payers and HTAs may consider data from digital endpoints in reimbursement and pricing decisions.
In this webinar, DiMe and our partners from Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer, and Savvy Co-op introduced a new suite of resources to support evidence generation strategies for the use of data generated by digital endpoints in value and reimbursement discussions for new drugs.